Back to Search
Start Over
A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
- Source :
-
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 May; Vol. 40, pp. 101978. Date of Electronic Publication: 2020 Jan 31. - Publication Year :
- 2020
-
Abstract
- A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in longstanding MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation.<br />Competing Interests: Declaration of Competing Interest All of the authors report no conflicts of interest.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2211-0356
- Volume :
- 40
- Database :
- MEDLINE
- Journal :
- Multiple sclerosis and related disorders
- Publication Type :
- Report
- Accession number :
- 32062445
- Full Text :
- https://doi.org/10.1016/j.msard.2020.101978